Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Retroperitoneal Lymph Node Dissection (RPLND)
Treatment for Testicular cancer
Typical Dosage: Surgical procedure
Effectiveness
90%
Safety Score
60%
Clinical Trials
7
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Surgical procedure
Time to Effect
Immediate (tumor removal)
Treatment Duration
Single procedure
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200
Monitoring:$3,000
Side Effect Mgmt:$1,000
Total Annual:$44,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
20
Outcome-Based Costs
Cost per Remission
$49,111
Comparison vs Active Surveillance
Cost Difference
+$30,000/year
More expensive
QALY Difference
-0.05 QALYs
Worse outcomes
Dominance
No dominance
Retroperitoneal Lymph Node Dissection (RPLND) Outcomes
for Testicular cancer
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
5 active trials recruiting for Retroperitoneal Lymph Node Dissection (RPLND) in Testicular cancer
Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma
NCT02537548ACTIVE NOT RECRUITINGNA
55 participants
INTERVENTIONAL
Loma Linda, United States +13 more
Started: Aug 28, 2015
R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma
NCT05345158RECRUITINGNA
25 participants
INTERVENTIONAL
Toronto, Canada
Started: Feb 23, 2022
A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
NCT06932458RECRUITINGPHASE2
30 participants
INTERVENTIONAL
London, Canada
Started: Jul 17, 2025
THERApy De-escalation for TESTicular Cancer
NCT06309745RECRUITING
30 participants
OBSERVATIONAL
London, United Kingdom
Started: Jun 24, 2024
Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.
NCT06593665RECRUITINGPHASE3
142 participants
INTERVENTIONAL
Indianapolis, United States +1 more
Started: Sep 10, 2024
Completed Clinical Trials
1 completed trial for Retroperitoneal Lymph Node Dissection (RPLND) in Testicular cancer
Role of Axumin PET Scan in Germ Cell Tumor
NCT03426865COMPLETED
10 participants
OBSERVATIONAL
Dallas, United States
Started: Mar 1, 2018